<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE us-patent-application SYSTEM "us-patent-application-v43-2012-12-04.dtd" [ ]><us-patent-application lang="EN" dtd-version="v4.3 2012-12-04" file="US20140005192A1-20140102.XML" status="PRODUCTION" id="us-patent-application" country="US" date-produced="20131218" date-publ="20140102"><us-bibliographic-data-application lang="EN" country="US"><publication-reference><document-id><country>US</country><doc-number>20140005192</doc-number><kind>A1</kind><date>20140102</date></document-id></publication-reference><application-reference appl-type="utility"><document-id><country>US</country><doc-number>13918048</doc-number><date>20130614</date></document-id></application-reference><us-application-series-code>13</us-application-series-code><classifications-ipcr><classification-ipcr><ipc-version-indicator><date>20060101</date></ipc-version-indicator><classification-level>A</classification-level><section>C</section><class>07</class><subclass>D</subclass><main-group>471</main-group><subgroup>04</subgroup><symbol-position>F</symbol-position><classification-value>I</classification-value><action-date><date>20140102</date></action-date><generating-office><country>US</country></generating-office><classification-status>B</classification-status><classification-data-source>H</classification-data-source></classification-ipcr><classification-ipcr><ipc-version-indicator><date>20060101</date></ipc-version-indicator><classification-level>A</classification-level><section>A</section><class>61</class><subclass>K</subclass><main-group>31</main-group><subgroup>506</subgroup><symbol-position>L</symbol-position><classification-value>I</classification-value><action-date><date>20140102</date></action-date><generating-office><country>US</country></generating-office><classification-status>B</classification-status><classification-data-source>H</classification-data-source></classification-ipcr><classification-ipcr><ipc-version-indicator><date>20060101</date></ipc-version-indicator><classification-level>A</classification-level><section>A</section><class>61</class><subclass>K</subclass><main-group>45</main-group><subgroup>06</subgroup><symbol-position>L</symbol-position><classification-value>I</classification-value><action-date><date>20140102</date></action-date><generating-office><country>US</country></generating-office><classification-status>B</classification-status><classification-data-source>H</classification-data-source></classification-ipcr><classification-ipcr><ipc-version-indicator><date>20060101</date></ipc-version-indicator><classification-level>A</classification-level><section>A</section><class>61</class><subclass>K</subclass><main-group>31</main-group><subgroup>5377</subgroup><symbol-position>L</symbol-position><classification-value>I</classification-value><action-date><date>20140102</date></action-date><generating-office><country>US</country></generating-office><classification-status>B</classification-status><classification-data-source>H</classification-data-source></classification-ipcr></classifications-ipcr><classifications-cpc><main-cpc><classification-cpc><cpc-version-indicator><date>20130101</date></cpc-version-indicator><section>C</section><class>07</class><subclass>D</subclass><main-group>471</main-group><subgroup>04</subgroup><symbol-position>F</symbol-position><classification-value>I</classification-value><action-date><date>20140102</date></action-date><generating-office><country>US</country></generating-office><classification-status>B</classification-status><classification-data-source>H</classification-data-source><scheme-origination-code>C</scheme-origination-code></classification-cpc></main-cpc><further-cpc><classification-cpc><cpc-version-indicator><date>20130101</date></cpc-version-indicator><section>A</section><class>61</class><subclass>K</subclass><main-group>31</main-group><subgroup>5377</subgroup><symbol-position>L</symbol-position><classification-value>I</classification-value><action-date><date>20140102</date></action-date><generating-office><country>US</country></generating-office><classification-status>B</classification-status><classification-data-source>H</classification-data-source><scheme-origination-code>C</scheme-origination-code></classification-cpc><classification-cpc><cpc-version-indicator><date>20130101</date></cpc-version-indicator><section>A</section><class>61</class><subclass>K</subclass><main-group>31</main-group><subgroup>506</subgroup><symbol-position>L</symbol-position><classification-value>I</classification-value><action-date><date>20140102</date></action-date><generating-office><country>US</country></generating-office><classification-status>B</classification-status><classification-data-source>H</classification-data-source><scheme-origination-code>C</scheme-origination-code></classification-cpc><classification-cpc><cpc-version-indicator><date>20130101</date></cpc-version-indicator><section>A</section><class>61</class><subclass>K</subclass><main-group>45</main-group><subgroup>06</subgroup><symbol-position>L</symbol-position><classification-value>I</classification-value><action-date><date>20140102</date></action-date><generating-office><country>US</country></generating-office><classification-status>B</classification-status><classification-data-source>H</classification-data-source><scheme-origination-code>C</scheme-origination-code></classification-cpc></further-cpc></classifications-cpc><classification-national><country>US</country><main-classification>5142342</main-classification><further-classification>544122</further-classification><further-classification>544328</further-classification><further-classification>514275</further-classification><further-classification>544230</further-classification><further-classification>435238</further-classification></classification-national><invention-title id="d0e43">INHIBITORS OF INFLUENZA VIRUSES REPLICATION</invention-title><us-related-documents><continuation><relation><parent-doc><document-id><country>US</country><doc-number>PCT/US2011/065371</doc-number><date>20111216</date></document-id><parent-status>PENDING</parent-status></parent-doc><child-doc><document-id><country>US</country><doc-number>13918048</doc-number></document-id></child-doc></relation></continuation><us-provisional-application><document-id><country>US</country><doc-number>61527273</doc-number><date>20110825</date></document-id></us-provisional-application><us-provisional-application><document-id><country>US</country><doc-number>61423943</doc-number><date>20101216</date></document-id></us-provisional-application></us-related-documents><us-parties><us-applicants><us-applicant sequence="00" app-type="applicant" designation="us-only" applicant-authority-category="assignee"><addressbook><orgname>Vertex Pharmaceuticals Incorporated</orgname><address><city>Cambridge</city><state>MA</state><country>US</country></address></addressbook><residence><country>US</country></residence></us-applicant></us-applicants><inventors><inventor sequence="00" designation="us-only"><addressbook><last-name>Charifson</last-name><first-name>Paul S.</first-name><address><city>Framingham</city><state>MA</state><country>US</country></address></addressbook></inventor><inventor sequence="01" designation="us-only"><addressbook><last-name>Clark</last-name><first-name>Michael P.</first-name><address><city>Concord</city><state>MA</state><country>US</country></address></addressbook></inventor><inventor sequence="02" designation="us-only"><addressbook><last-name>Bandarage</last-name><first-name>Upul K.</first-name><address><city>Lexington</city><state>MA</state><country>US</country></address></addressbook></inventor><inventor sequence="03" designation="us-only"><addressbook><last-name>Davies</last-name><first-name>Ioana</first-name><address><city>Watertown</city><state>MA</state><country>US</country></address></addressbook></inventor><inventor sequence="04" designation="us-only"><addressbook><last-name>Duffy</last-name><first-name>John P.</first-name><address><city>Northborough</city><state>MA</state><country>US</country></address></addressbook></inventor><inventor sequence="05" designation="us-only"><addressbook><last-name>Gao</last-name><first-name>Huai</first-name><address><city>Arlington</city><state>MA</state><country>US</country></address></addressbook></inventor><inventor sequence="06" designation="us-only"><addressbook><last-name>Feng</last-name><first-name>Jun</first-name><address><city>Acton</city><state>MA</state><country>US</country></address></addressbook></inventor><inventor sequence="07" designation="us-only"><addressbook><last-name>Liang</last-name><first-name>Jianglin</first-name><address><city>Needham</city><state>MA</state><country>US</country></address></addressbook></inventor><inventor sequence="08" designation="us-only"><addressbook><last-name>Kennedy</last-name><first-name>Joseph M.</first-name><address><city>Charlestown</city><state>MA</state><country>US</country></address></addressbook></inventor><inventor sequence="09" designation="us-only"><addressbook><last-name>Ledeboer</last-name><first-name>Mark W.</first-name><address><city>Acton</city><state>MA</state><country>US</country></address></addressbook></inventor><inventor sequence="10" designation="us-only"><addressbook><last-name>Ledford</last-name><first-name>Brian</first-name><address><city>Norton</city><state>MA</state><country>US</country></address></addressbook></inventor><inventor sequence="11" designation="us-only"><addressbook><last-name>Maltais</last-name><first-name>Francois</first-name><address><city>Tewksbury</city><state>MA</state><country>US</country></address></addressbook></inventor><inventor sequence="12" designation="us-only"><addressbook><last-name>Perola</last-name><first-name>Emanuele</first-name><address><city>Brookline</city><state>MA</state><country>US</country></address></addressbook></inventor></inventors></us-parties><assignees><assignee><addressbook><orgname>Vertex Pharmaceuticals Incorporated</orgname><role>02</role><address><city>Cambridge</city><state>MA</state><country>US</country></address></addressbook></assignee></assignees></us-bibliographic-data-application><abstract id="abstract"><p id="p-0001" num="0000">Methods of inhibiting the replication of influenza viruses in a biological sample or patient, of reducing the amount of influenza viruses in a biological sample or patient, and of treating influenza in a patient, comprises administering to said biological sample or patient an effective amount of a compound represented by Structural Formula (I):</p><p id="p-0002" num="0000"><chemistry id="CHEM-US-00001" num="00001"><img id="EMI-C00001" he="38.02mm" wi="69.85mm" file="US20140005192A1-20140102-C00001.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0003" num="0000">or a pharmaceutically acceptable salt thereof, wherein the values of Structural Formula (I) are as described herein. A compound is represented by Structural Formula (I) or a pharmaceutically acceptable salt thereof, wherein the values of Structural Formula (I) are as described herein. A pharmaceutical composition comprises an effective amount of such a compound or pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier, adjuvant or vehicle.</p></abstract></us-patent-application>